CA3062814C — Stable cannabinoid formulations
Assigned to Radius Pharmaceuticals Inc · Expires 2023-11-14 · 3y expired
What this patent protects
The present invention is generally directed to substantially pure cannabidiol of the formula: The present invention is also directed to stable cannabinoid pharmaceutical formulations comprising cannabidiol and a vehicle, and methods of their use for treating Prader-Willi syndr…
USPTO Abstract
The present invention is generally directed to substantially pure cannabidiol of the formula: The present invention is also directed to stable cannabinoid pharmaceutical formulations comprising cannabidiol and a vehicle, and methods of their use for treating Prader-Willi syndrome, one or more symptoms of Prader-Willi syndrome and childhood absence epilepsy.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.